Due to concerns regarding the spread of COVID-19 and the impact it is having on hospitals, clinics, physician offices, and clinical trial participants’ ability to travel, the NCI, DCP is providing clarification on measures to address some of the current challenges in providing care to participants enrolled on clinical trials in order to mitigate immediate hazards to the patients.
Guidance is also provided for identifying and reporting COVID-19 related Adverse and Serious Adverse Events, as well as minor deviations which are to be reported on the COVID Minor Deviation Reporting Form.
Please refer to the DCP-issued memorandums regarding COVID-19 for the latest information.
